Aclaris Therapeutics Q2 revenue beats analyst estimates

Aclaris Therapeutics

06/08/2026 12:10

Overview
U.S. biopharma's Q2 revenue fell yr/yr but beat analyst expectations
Net loss for Q2 widened and missed analyst estimates
Company reaffirmed cash runway through 2028 and highlighted pipeline progress

Outlook
Aclaris expects top line results from Phase 1b ATI-052 trials in asthma and atopic dermatitis in H2 2026
Company plans to initiate Phase 2b ATI-052 program in asthma and atopic dermatitis in Q4 2026
Aclaris expects its cash position to fund operations through the end of 2028

Result Drivers
R&D SPENDING - Higher research and development expenses driven by ATI-052 clinical and manufacturing costs
ROYALTY REVENUE - Six-month revenue increase attributed to higher royalties from Lilly and Sun Pharma license agreements
G&A COSTS - General and administrative expense increase due to higher professional, legal, and personnel expenses

Company press release: ID:nGNX2fynwR

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.63 mln
$1.38 mln (9 Analysts)
Q2 Net Loss
Miss
$21.51 mln
$21.26 mln (9 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aclaris Therapeutics, Inc. is $10.00, about 57.2% above its August 5 closing price of $6.36

Reuters Recommended Reads
Aug 5 - Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Aug 5 - Vanda Pharmaceuticals Q2 loss widens on lower sales, higher costs
Aug 5 - Enliven Therapeutics Q2 net loss widens on higher expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)